Our data suggest that MYC overexpression compensates for lack of HIF-1 activity in hypoxic SCLC and that targeting regulatory steps in the glutaminolysis and lipogenesis pathways might be novel strategies to eradicate MYC amplified tumor cells. Here, HIF1A is linked to neoplasm.